Biotech and the money flowing into biotech stocks has been 99.99% focused on a covid-19 Vaccine. Pfizer (NYSE: PFE) has announced their vaccine with Moderna (NASAQ: MRNA) soon to follow. Pfizer has had a great run from $35 to $42 and Moderna equaling in percentage from $66 to $90.
But where is the value now? One thing to stay cautious of is the companies running on sheer hype like AstraZeneca (NASDA: AZN) and Novavax (NASDAQ: NVAX). At one point in time, these companies were considered front runners in the space. If their efforts fail to come to fruition, they could be looking at very fast declines in their stock. Novavax gave back 50% of its value over the past three months.
Other companies focused on testing like OPKO Health, Inc. (NYSE: OPK) and Abbott Labs (NYSE: ABT) could also subside as a vaccine would weaken any demand for covid tests.
There is a niche biotech company called PetVivo, Holdings, Inc. (OTCQB: PETV). They are an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets. PetVivo is benefiting from trials on the human side with a lower barrier to approval for pets.
The company just announced a sponsored research agreement with Colorado State University (“CSU”) College of Veterinary Medicine and Biomedical Sciences to engage in a clinical study involving the treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH
KUSH, a veterinarian-administered intraarticular injection for the treatment of osteoarthritis in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Sales in the $4.8 billion dog and horse therapeutics market is expected to begin shortly.
Felix Duerr, DVM, associate professor of small animal orthopedics, will serve as Principal Investigator for the research project. Dr. Duerr established and now oversees CSU’s Orthopedic Medicine and Mobility program. His clinical interests include sports medicine and rehabilitation, and minimally invasive surgery, including arthroscopy.
PetVivo Holdings, Inc. (OTCQB: PETV) also recently announced that a company out of Orlando, Florida called nScrypt that designs and manufactures high-precision industrial Micro-dispensing and Direct Digital Manufacturing equipment, has just successfully 3D bio-printed PetVivo’s (OTCQB: PETV) biomaterial for orthopedic implants using its Bio-Fabrication Tool (BAT). To the best of the company’s knowledge, there is no other company that has the ability to provide these life-based components for the 3D printing marketplace.
The applications and cures for this technology are endless. Implants, replacements, up until and including the present, have been made with foreign ingredients like titanium and other metals. The future of this science now lies with the technology that allows for a more biologically familiar biomaterial. PetVivo’s biomaterial is made from the same components as the body’s natural tissue, allowing cells to be added to the structures being printed.
Ultimately, this breakthrough could lead to the creation of implants that actually mimic the bone itself.
Currently PetVivo Holdings, Inc. (OTCQB: PETV) has only 24 million shares outstanding and a market cap of $40 million.
Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: – Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”
Goldman Research just announced a new report with its current target price under review. You can see the report here:Pet Vivo (OTCQB: PETV) also has a portfolio of 19 patents that protect the company’s pipeline of 16 products for the treatment of animals and people.